The Michael J. Fox Foundation for Parkinson's Research
  Research
  News & Events
  Funding Programs
  About

PD Online Research

Alzheimer Research Forum
  Current Papers
  ARF Recommends
  Research News
PDGene - Gene overview of all published PD-association studies for SNCA
Back Search Methods Disclaimer Credits
 Gene: SNCA  (PD1; NACP; PARK1; PARK4; MGC110988)  Entrez Gene    View on AlzGene
 Protein: alpha-synuclein  (alpha-synuclein, isoform NACP140; non A-beta component of AD amyloid; non A4 component of amyloid precursor)  ProteinLink
 Chromosome: 4   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 11 February 2013 ;  ***Note that in addition to SNCA, the gene MMRN1 in this locus shows genome-wide significant effects in PDGene meta-analyses. As statistical significance is currently weaker than for SNCA, MMRN1 is not listed in the top results, but can be accessed via the PDGene search function.***
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      PD Cases Normal Controls  
Study Population Source # Polys # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
 Caucasian
Autere, 2002
Finland CL,PO  1  (detail)  112
(48%)
M--67
(55%)
72.7 + 5.2
(-)
Negative
Botta-Orfila, 2010
Overlaps with
Mata, 2011 (Spain)
CL  1  (detail)  757
(43%)
C-68.3 + 10.4
(-)
708
(58%)
69.4 + 13.4
(-)
n.a.
Brighina, 2008
Overlaps with
Maraganore, 2006
CL  1  (detail)  361
(35%)
C65.1
(23-88)
70.2
(42-90)
361
(35%)
70.9
(45-93)
n.a.
Cardo, 2011
Spain CL  1  (detail)  1169
(45%)
C--772
(58%)
64 + 17
(18-100)
Positive
Chung, 2010
Overlaps with
Maraganore, 2006
CL  1  (detail)  449
(35%)
-64.7
(23-88)
70.3
(44-90)
449
(35%)
71.8
(45-93)
Trend
Chung, 2010
USA CL  18  (detail)  449
(35%)
-64.7
(23-88)
70.3
(44-90)
449
(35%)
71.8
(45-93)
Trend
Do, 2011
USA (23andMe-GWAS) CL  1  (detail)  3426
(40%)
M57.4 + 10.7
(-)
64.3 + 10.6
(-)
29624
(42%)
48.2 + 16
(-)
Positive
Edwards, 2010
USA (HIHG-GWAS) CL  1  (detail)  604
(37%)
C56.3 + 12.9
(-)
64.5 + 12.1
(-)
619
(66%)
69.3 + 9.8
(-)
Positive
Elbaz, 2010
Australia (Mellick) CL,PO  4  (detail)  929
(38%)
C59.4 + 11.4
(-)
72.3 + 10.2
(-)
713
(64%)
66.6 + 9.9
(-)
Positive
Elbaz, 2010
Norway (Aasly) CL  4  (detail)  603
(42%)
C59.3 + 10.9
(-)
73.5 + 10.7
(-)
526
(44%)
71.3 + 12.5
(-)
Positive
Elbaz, 2010
Overlaps with
IPDGC, 2011 (France/Chartier-Harlin)
CL  4  (detail)  563
(46%)
C54.7 + 11.5
(-)
63.8 + 10.4
(-)
143
(55%)
65.2 + 11
(-)
Positive
Elbaz, 2010
Overlaps with
IPDGC, 2011 (Germany/Klein)
CL  4  (detail)  522
(42%)
C43.9 + 12.9
(-)
61.5 + 12.3
(-)
289
(53%)
54.9 + 13.9
(-)
Positive
Elbaz, 2010
USA (Wzsolek) CL  4  (detail)  378
(45%)
C62.1 + 11.9
(-)
71 + 11.2
(-)
364
(48%)
72.9 + 10.8
(-)
Positive
Elbaz, 2010
Ireland (Lynch) CL  4  (detail)  361
(42%)
C51.4 + 10.4
(-)
67.4 + 10.2
(-)
445
(64%)
66.6 + 24.2
(-)
Positive
Elbaz, 2010
Poland (Opala) CL,PO  4  (detail)  349
(38%)
C57.1 + 11.6
(-)
70.1 + 10.6
(-)
340
(54%)
64.3 + 15.7
(-)
Positive
Elbaz, 2010
Overlaps with
Simon-Sanchez, 2009 (Germany/Krueger)
CL,PO  4  (detail)  335
(41%)
C-52.1 + 12.5
(-)
339
(45%)
53.2 + 12.2
(-)
Positive
Elbaz, 2010
Greece (Hadjigeorgiou) CL  4  (detail)  322
(50%)
C64.6 + 9.4
(-)
68.8 + 9.1
(-)
315
(50%)
70 + 8.6
(-)
Positive
Elbaz, 2010
Overlaps with
IPDGC, 2011 (Germany/Auberger)
CL  4  (detail)  232
(49%)
C56.2 + 10.8
(-)
71.9 + 11.4
(-)
47
(36%)
58.8 + 9.8
(-)
Positive
Elbaz, 2010
Italy (Annesi) CL,PO  4  (detail)  190
(47%)
C61.3 + 9.4
(-)
71.8 + 9.4
(-)
168
(54%)
53.6 + 9.1
(-)
Positive
Elbaz, 2010
Italy (Valente) CL,PO  4  (detail)  189
(49%)
C58.4 + 8.2
(-)
67.6 + 8.5
(-)
95
(55%)
69 + 9.8
(-)
Positive
Elbaz, 2010
Greece (Bozi) CL  4  (detail)  135
(41%)
C66.4 + 10.7
(-)
72.6 + 10.4
(-)
95
(56%)
71.3 + 9.5
(-)
Positive
Elbaz, 2010
Italy (Ferrarese) CL  4  (detail)  103
(47%)
C62.3 + 10.4
(-)
67.8 + 9.6
(-)
102
(38%)
62.1 + 6.6
(-)
Positive
Elbaz, 2010
Sweden (Wirdefeldt) CL,PO  4  (detail)  91
(44%)
C65.7 + 11
(-)
75.6 + 8.8
(-)
180
(56%)
73.7 + 10.1
(-)
Positive
Farrer, 2001
Overlaps with
Maraganore, 2006
CL  5  (detail)  319
(-)
C64
(31-91)
-196
(-)
72
(37-94)
Positive
Ferrarese, 2001
Italy CL  1  (detail)  38
(-)
C--28
(-)
-Negative
Fung, 2006
Overlaps with
Simon-Sanchez, 2009 (USA)
CL  17  (detail)  267
(-)
C--270
(-)
68
(55-88)
n.a.
Gatto, 2010
USA (PEG) CL,CO  3  (detail)  333
(45%)
C--336
(50%)
-Positive
Goris, 2007
Overlaps with
IPDGC, 2011 (UK)
CL  1  (detail)  659
(-)
C--2176
(-)
-n.a.
Hadjigeorgiou, 2005
Overlaps with
Maraganore, 2006
CL  1  (detail)  178
(40%)
C63.3 + 9.6
(30-88)
69.5 + 9.7
(44-95)
186
(45%)
68.3 + 11.9
(32-93)
n.a.
Hamza, 2010
USA (NGRC-GWAS) CL  5  (detail)  2000
(33%)
C58.3 + 11.9
(-)
67.2 + 10.6
(-)
1986
(61%)
70.3 + 14
(21-90)
Positive
Holzmann, 2003
Germany CL  2  (detail)  315
(44%)
C55.4 + 11.4
(-)
66 + 11.2
(-)
370
(48%)
72 + 4.3
(-)
Negative
IPDGC, 2011
France (GWAS) CL,PO  1  (detail)  1039
(41%)
U48.9 + 48.9
(-)
-1984
(33%)
73.7 + 5.4
(-)
Positive
IPDGC, 2011
France (REP-Immuno) CL  1  (detail)  267
(-)
U--363
(-)
-Positive
IPDGC, 2011
Germany (REP-Immuno) CL  1  (detail)  1153
(-)
U--712
(-)
-Positive
IPDGC, 2011
Iceland (REP-in silico) CL,PO  1  (detail)  479
(-)
C--1427
(-)
-Positive
IPDGC, 2011
Netherlands (REP-in silico) CL,PO  1  (detail)  824
(-)
U--2082
(-)
-Positive
IPDGC, 2011
UK (REP-Immuno) CL  1  (detail)  1271
(-)
U--1864
(-)
-Positive
IPDGC, 2011
USA (PROGENI/GenePD-GWAS) CL  1  (detail)  876
(40%)
U61.5 + 61.5
(-)
-857
(60%)
-Positive
IPDGC, 2011
USA (NINDS-GWAS) CL  1  (detail)  971
(40%)
U55.9 + 55.9
(-)
-3034
(53%)
62 + 15.6
(-)
Positive
IPDGC, 2011
USA (REP-Immuno) CL  1  (detail)  2807
(-)
U--2215
(-)
-Positive
IPDGC, 2011
Germany (GWAS) CL  1  (detail)  742
(40%)
U56 + 56
(-)
-944
(48%)
-Positive
IPDGC, 2011
Netherlands (REP-Immuno) CL  1  (detail)  304
(-)
U--402
(-)
-Positive
IPDGC, 2011
UK (WTCCC-GWAS) CL,PO  1  (detail)  1705
(43%)
U--5200
(50%)
-Positive
Kay, 2008
USA (Oregon) CL  1  (detail)  601
(35%)
C58 + 11.7
(24-87)
68.1 + 10.3
(30-91)
1220
(62%)
68.9 + 21.9
(20-109)
Positive
Kay, 2008
USA (Washington) CL  1  (detail)  665
(26%)
C58.5 + 11.8
(25-89)
67.8 + 10.9
(29-95)
560
(64%)
66 + 12.4
(26-99)
Positive
Kay, 2008
USA (New York) CL  1  (detail)  393
(38%)
C59.7 + 11.6
(29-93)
68.4 + 10.8
(35-95)
271
(63%)
65.5 + 10.7
(34-93)
Positive
Kay, 2008
USA (Georgia) CL  1  (detail)  143
(37%)
C58.3 + 11.3
(30-92)
67 + 10.2
(39-96)
78
(69%)
68.5 + 8
(50-83)
Positive
Kay, 2010
Overlaps with
Mata, 2010 (USA-NGRC)
CL  2  (detail)  2091
(32%)
C58.3 + 12.1
(8-93)
67.3 + 10.7
(21-96)
1686
(56%)
66.1 + 13.1
(25-99)
n.a.
Khan, 2001
UK CL  2  (detail)  305
(45%)
M57
(-)
61 + 6
(-)
330
(47%)
63 + 7
(-)
Negative
Kruger, 1999
Overlaps with
Maraganore, 2006 (Germany)
CL  1  (detail)  236
(44%)
C61.1 + 7.6
(-)
66.5 + 11
(-)
200
(-)
-n.a.
Mamah, 2005
Overlaps with
Maraganore, 2006
CL  1  (detail)  161
(-)
C--161
(-)
-n.a.
Maraganore, 2005
Overlaps with
Chung, 2010 (USA)
CL  2  (detail)  332
(42%)
C63
(36-88)
68
(42-90)
332
(42%)
67
(42-91)
Negative
Maraganore, 2006
France (Elbaz) CO  1  (detail)  200
(43%)
C65
(35-75)
69
(37-76)
444
(41%)
69
(36-79)
Positive
Maraganore, 2006
Italy (Ferrarese) CL  1  (detail)  114
(39%)
C58
(37-77)
67
(44-86)
112
(29%)
66
(48-77)
Positive
Maraganore, 2006
Greece (Hadjigeorgiou) CO  1  (detail)  152
(40%)
C65
(32-88)
72
(40-95)
120
(47%)
69
(32-89)
Positive
Maraganore, 2006
Belgium (Van Broeckhoven) CO  1  (detail)  186
(41%)
C57
(28-75)
66
(40-87)
188
(45%)
64
(28-89)
Positive
Maraganore, 2006
USA (Ashizawa) CL  1  (detail)  100
(41%)
C53
(28-80)
65
(32-84)
100
(51%)
60
(22-75)
Positive
Maraganore, 2006
USA (Checkoway) CO  1  (detail)  160
(40%)
C65
(35-75)
68
(40-88)
240
(44%)
72
(45-82)
Positive
Maraganore, 2006
Italy (Quattrone) CO  1  (detail)  190
(42%)
C58
(34-84)
68
(43-88)
181
(55%)
74
(56-93)
Positive
Maraganore, 2006
Germany (Riess) CL  1  (detail)  163
(44%)
C56
(22-87)
68
(38-91)
738
(49%)
73
(65-83)
Positive
Maraganore, 2006
Norway (Aasly) CL,PO  1  (detail)  401
(38%)
C60
(25-88)
70
(41-92)
545
(44%)
62
(46-96)
Positive
Maraganore, 2006
USA (Maraganore) CL,PO  1  (detail)  678
(37%)
C63
(28-88)
68
(31-99)
182
(63%)
72
(37-94)
Positive
Maraganore, 2006
Australia (Mellick) CL,PO  1  (detail)  373
(45%)
C61
(26-86)
68
(33-89)
375
(70%)
66
(20-89)
Positive
Mata, 2010
USA (NGRC-Tier1) CL  13  (detail)  685
(-)
C--673
(-)
-Positive
Mata, 2010
USA (NGRC-Tier2) CL  5  (detail)  1271
(-)
C--1439
(-)
-Positive
Mata, 2011
Spain CL  1  (detail)  1445
(44%)
C60 + 12.2
(-)
68.1 + 11.2
(-)
1161
(58%)
68.9 + 11.2
(-)
Positive
McCulloch, 2008
Overlaps with
Kay, 2008 (Oregon)
CL  1  (detail)  172
(38%)
C-65.9
(39-87)
96
(55%)
67.8
(21-83)
n.a.
McCulloch, 2008
Overlaps with
Kay, 2008 (Washington)
CL  1  (detail)  391
(26%)
C-67.3
(32-95)
293
(58%)
67.3
(30-93)
n.a.
McCulloch, 2008
Overlaps with
Kay, 2008 (New York)
CL  1  (detail)  253
(35%)
C-68.1
(40-95)
214
(66%)
64.6
(34-94)
n.a.
McCulloch, 2008
Overlaps with
Kay, 2008 (Georgia)
CL  1  (detail)  116
(37%)
C-67.3
(40-97)
61
(67%)
68.5
(51-84)
n.a.
Mellick, 2005
Overlaps with
Maraganore, 2006
CL  1  (detail)  369
(44%)
C60 + 10
(-)
67 + 10
(-)
370
(69%)
64 + 11
(-)
n.a.
Mueller, 2005
Overlaps with
Simon-Sanchez, 2009 (Germany-I)
CL  33  (detail)  340
(42%)
C--680
(-)
-Positive
Mueller, 2005
Overlaps with
Simon-Sanchez, 2009 (Germany-II)
CL  16  (detail)  329
(40%)
C--322
(-)
-Positive
Myhre, 2008
Overlaps with
Elbaz, 2010 (Norway)
CL  10  (detail)  236
(41%)
C58.2 + 11.4
(-)
69.9 + 10.9
(-)
236
(-)
69.7 + 10.9
(-)
Positive
Pals, 2004
Belgium CL  18  (detail)  175
(41%)
C57
(28-75)
66
(40-87)
186
(45%)
64
(28-89)
Positive
Pankratz, 2008
USA (PROGENI, GenePD) CL  110  (detail)  857
(41%)
C61.9 + 10.8
(-)
-867
(60%)
54.8 + 13.1
(-)
Positive
Pankratz, 2009
Overlaps with
IPDGC, 2011 (USA-GenePD)
CL  5  (detail)  737
(40%)
C61.8
(18-84)
-359
(56%)
70.3
(55-92)
Positive
Parsian, 1998
Overlaps with
Parsian, 2007
CL  1  (detail)  216
(35%)
C--174
(36%)
-n.a.
Parsian, 2007
USA CL  3  (detail)  521
(36%)
C60.1
(21-85)
68
(-)
215
(42%)
62 + 14
(-)
Positive
Pastor, 2001
Spain CL  1  (detail)  167
(-)
C56.6 + 11
(-)
-169
(34%)
12
(-)
Negative
Payami, 2009
Re-analysis of Kay, 2008 CL  1  (detail)  ------n.a.
Rajput, 2009
Canada CL  4  (detail)  452
(37%)
C62
(-)
71
(41-92)
245
(70%)
65
(18-92)
Positive
Rhodes, 2010
USA PO  1  (detail)  273
(45%)
C69 + 10.4
(34-88)
-306
(49%)
-Negative
Ross, 2002
Ireland CL  1  (detail)  98
(48%)
C--92
(70%)
-Negative
Ross, 2007
Overlaps with
Elbaz, 2010 (Ireland)
CL  14  (detail)  186
(61%)
C-61 + 12
(-)
186
(61%)
-Positive
Saad, 2010
France (GWAS) CL  5  (detail)  1039
(41%)
C48.9 + 12.8
(-)
57.5 + 16.6
(-)
1984
(43%)
73.7 + 5.4
(-)
Positive
Saad, 2010
Overlaps with
Simon-Sanchez, 2009 (WTCCC-GWAS)
CL  4  (detail)  1705
(42%)
C--5200
(50%)
51
(-)
Positive
Simon-Sanchez, 2009
USA, Germany, UK (Stage II) CL,PO  8  (detail)  3452
(32%)
M61.1
(-)
-4756
(39%)
-Positive
Simon-Sanchez, 2009
USA, Germany (GWAS) CL,PO  33  (detail)  1745
(45%)
C55.8
(7-98)
-4047
(50%)
-Positive
Simon-Sanchez, 2009
USA (NINDS-GWAS) CL  75  (detail)  931
(40%)
C--790
(58%)
-Negative
Simon-Sanchez, 2011
Netherlands (GWAS) CL,PO  28  (detail)  772
(36%)
U55.3
(16-84)
62.3
(29-89)
2024
(56%)
53.7
(45-95)
Positive
Spadafora, 2003
Overlaps with
Maraganore, 2006
CL  1  (detail)  189
(43%)
C-66.2 + 8.7
(-)
182
(55%)
74.9 + 7.5
(-)
n.a.
Spencer, 2010
Overlaps with
Simon-Sanchez, 2009 (WTCCC-GWAS)
CL,PO  3  (detail)  1705
(-)
C--5175
(-)
-Positive
Spencer, 2010
Overlaps with
Saad, 2010 (France-GWAS)
CL  1  (detail)  1039
(-)
C--1984
(-)
-n.a.
Sutherland, 2009
Overlaps with
Maraganore, 2006
CL  9  (detail)  331
(51%)
C60.1 + 10.6
(-)
70.3 + 8.7
(-)
296
(51%)
70.5 + 8.9
(-)
Trend
Tan, 2000
Overlaps with
Maraganore, 2006
CL  1  (detail)  100
(-)
C53.4 + 11.5
(28-80)
61 + 12
(32-82)
100
(-)
57.1 + 12.2
(22-74)
n.a.
Trotta, 2011
Italy CL  10  (detail)  904
(40%)
C56.1 + 11
(-)
66.6 + 10.9
(-)
891
(66%)
62.4 + 14.6
(-)
Positive
Westerlund, 2008
Sweden CL  3  (detail)  290
(-)
C60.3
(-)
68
(-)
313
(-)
58.3
(-)
Positive
Wider, 2010
Overlaps with
Elbaz, 2010 (USA)
CL  1  (detail)  286
(44%)
C62 + 12
(16-85)
73 + 11
(39-92)
322
(45%)
72 + 11
(33-90)
n.a.
Wider, 2010
Overlaps with
Elbaz, 2010 (Norway)
CL  1  (detail)  420
(40%)
C59 + 11
(35-88)
73 + 11
(45-99)
464
(44%)
70 + 12
(43-106)
n.a.
Wider, 2010
Overlaps with
Elbaz, 2010 (Ireland)
CL  1  (detail)  314
(41%)
C52 + 11
(18-77)
66 + 10
(37-91)
309
(63%)
71 + 23
(23-102)
n.a.
Winkler, 2007
* Recently Updated *
Overlaps with
Schmitt, 2012 (Germany/Klein)
CL  14  (detail)  234
(-)
C--160
(-)
-Positive
Winkler, 2007
Serbia CL  14  (detail)  163
(-)
C--110
(-)
-Positive
Xia, 2001
USA CL  1  (detail)  53
(-)
C--138
(-)
-Negative
 Asian
Chang, 2011
China CL  2  (detail)  636
(41%)
C55.8 + 11.1
(17-85)
-510
(43%)
52.4 + 14
(15-91)
Positive
Hu, 2010
China CL  1  (detail)  330
(46%)
C52.6 + 11.8
(-)
-300
(-)
-Negative
Hu, 2011
China CL  1  (detail)  110
(45%)
C56.7 + 10.8
(25-79)
59.8 + 10.5
(-)
136
(44%)
59.9 + 9.1
(-)
Positive
Izumi, 2001
Japan CL  1  (detail)  200
(60%)
C61 + 9.1
(-)
-250
(52%)
61.1 + 13.4
(-)
Negative
Kim, 2010
Korea CL  1  (detail)  878
(56%)
C56.6 + 9.5
(23-85)
64.2 + 9
(33-91)
559
(54%)
58.5 + 10.6
(37-85)
Positive
Kobayashi, 2006
Japan CL  22  (detail)  185
(63%)
C62
(28-83)
-191
(65%)
69
(20-92)
Positive
Mizuta, 2002
Japan CL  1  (detail)  165
(59%)
C56 + 11
(-)
64 + 9.6
(-)
155
(63%)
63 + 8.6
(-)
Negative
Mizuta, 2006
Overlaps with
Mizuta, 2008
CL  26  (detail)  882
(56%)
C57.4 + 10.9
(-)
64.9 + 9.8
(-)
938
(48%)
45.3 + 16.3
(-)
Positive
Mizuta, 2008
Japan (II) CL  1  (detail)  521
(54%)
C58.8 + 11.4
(-)
67.2 + 9.7
(-)
1003
(54%)
-Positive
Mizuta, 2008
Japan (I) CL  1  (detail)  882
(56%)
C57.4 + 10.9
(-)
-938
(48%)
45.3 + 16.3
(-)
Positive
Satake, 2009
Japan (Replication-2) CL  4  (detail)  321
(55%)
C63.7 + 9.7
(-)
-1614
(55%)
59.1 + 19.1
(-)
Positive
Satake, 2009
Japan (Replication-1) CL  4  (detail)  612
(50%)
C43 + 13.8
(20-80)
-14139
(42%)
60.1 + 12.6
(-)
Positive
Satake, 2009
Japan (GWAS) CL  4  (detail)  1078
(55%)
C-58.8 + 10.1
(22-88)
2628
(45%)
49.9 + 14.2
(-)
Positive
Tan, 2003
Singapore (I) CL  1  (detail)  104
(45%)
C59 + 10.3
(-)
63.9 + 10.1
(27-88)
105
(45%)
63.8 + 10.2
(26-88)
Trend
Tan, 2003
Singapore (II) CL  1  (detail)  105
(45%)
C59.1 + 10.6
(-)
64.5 + 9.9
(34-91)
105
(45%)
64.3 + 9.9
(34-93)
Trend
Tan, 2004
China CL  7  (detail)  214
(44%)
C-64.8 + 9.6
(27-91)
234
(44%)
64.3 + 9.9
(26-92)
Positive
Tan, 2010
Singapore CL  3  (detail)  433
(44%)
C60
(-)
64
(-)
916
(40%)
56
(-)
Positive
Wang, 2006
Taiwan CL  2  (detail)  252
(50%)
C-67.6
(37-91)
257
(48%)
60.1
(23-98)
Positive
Wang, 2012
China CL,PO  1  (detail)  2013
(39%)
C58.6 + 10.4
(-)
62.7 + 10.1
(-)
1971
(42%)
64.9 + 8.3
(-)
Positive
Yu, 2010
China CL  1  (detail)  332
(-)
C--300
(-)
-Positive
 Other/Mixed
Ding, 2011
USA CL  1  (detail)  344
(38%)
C61 + 11.5
(-)
66.4 + 10.8
(-)
275
(-)
-Positive
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds  
Study Population # Polys # Families # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
 Caucasian
Brighina, 2008
Overlaps with
Maraganore, 2006
 1  (detail)  472472
(38%)
C59.5
(31-87)
65.3
(33-91)
472
(49%)
64.4
(32-87)
Positive
Chung, 2010
USA  19  (detail)   654
(36%)
C60.4
(28-87)
66.3 + 30.8
(-)
654
(50%)
65.1
(32-90)
Trend
Mamah, 2005
Overlaps with
Maraganore, 2006
 1  (detail)  396396
(-)
U--396
(-)
-n.a.
Maraganore, 2005
Overlaps with
Chung, 2010 (USA)
 14  (detail)  443443
(39%)
C61
(31-94)
68
(33-96)
443
(52%)
66
(29-90)
Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine PD diagnosis ->  "C" (clinical PD diagnosis), "N" (neuropathological PD diagnosis), "M" (mixed, i.e. PD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
PDGene Recent Updates
PDGene Top Results
PDGene Stats
Studies: 881
Genes: 915
Polymorphisms: 3446
Meta-analyses: 889
PDGene Links
GEO-PD Meeting 2012
PDmutDB
Curated by the VIB Department of Molecular Genetics of the University of Antwerp
Parkinson's disease Mutation Database
Curated by Parkinson's Institute from Leiden University Medical Center
Mutation Database for Parkinson's Disease
Curated by the Institute for Infocomm Research in Singapore
Michael J. Fox Foundation
The PDGene database is supported by a grant from The Michael J. Fox Foundation in partnership with the Alzheimer Research Forum.
PD Online Research
Alzheimer Research Forum
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
Copyright © 2014 Biomedical Research Forum LLC Disclaimer Copyright